SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $3,298,051,614 |
| Positions | 33 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| APOGEE THERAPEUTICS INC | APGE | COM | $1,127,318,496 | 8,493,321 |
| ORUKA THERAPEUTICS INC | ORKA | COM | $394,805,893 | 4,148,428 |
| ERASCA INC | ERAS | COM | $327,777,996 | 17,891,812 |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $265,048,073 | 2,985,448 |
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $115,026,400 | 1,180,000 |
| OCULAR THERAPEUTIX INC | OCUL | COM | $101,606,813 | 10,346,926 |
| DAMORA THERAPEUTICS INC | DMRA | COM NEW | $93,729,506 | 3,603,595 |
| SAVARA INC | SVRA | COM | $90,835,009 | 14,745,943 |
| JADE BIOSCIENCES INC | JBIO | COM NEW | $71,556,488 | 3,220,364 |
| COGENT BIOSCIENCES INC | COGT | COM | $63,551,824 | 1,642,166 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.